Twenty patients with chronic bronchitis were given incremental dosages of a new slow release preparation of theophylline and observed for its effect on lung function and exercise tolerance. Measurements were made subjectively by using visual analogue scales and objectively using six minute walking distances and spirometry. The study was placebo controlled and had a double blind randomised design.
Introduction
Methylxanthines are routinely prescribed for patients with chronic bronchitis, yet their efficacy in this condition is not established. Small dose related improvements in spirometric function have been reported with short' and more long term treatment but such benefits are not always found. 2 There is also evidence that aminophylline may improve the contractility of skeletal3 4and diaphragmatic' muscle. This raises the possibility that these drugs might reduce the susceptibility of the muscles of the inspiratory apparatus to muscular fatigue.5 Such fatigue may play an important part in the effort dyspnoea so commonly encountered in patients with chronic bronchitis.
Surprisingly few studies have observed the effect of theophylline on this effort intolerance, and even these have produced conflicting results.6 I report the effects of incremental dosages of a new slow release theophylline preparation (Uniphyllin Unicontin) on pulmonary function and everyday exercise measured both subjectively (visual analogue scales) and objectively (six minute walking distances)8 in 20 patients with chronic bronchitis.
Patients and methods
The 20 patients had a mean age of 66 years (range 45-75), a mean height of 169 cm (range 150-185), and a mean weight of 58 kg (range 35-97); their mean forced expiratory volume in one second (FEV1) was 0 8 1 (range 0-3-1 5). The patients were studied on six occasions over three weeks. The Glamorgan CF47 ODT W V EVANS, MRCP, consultant physician ness was rated immediately after exercise using a 100 mm vertical visual analogue scale (0= no dyspnoea, 100 = maximum tolerable dyspnoea), which the patients marked for themselves. After a rest period of one hour the spirometric and walking tests were repeated.
Data from both walks on each study day were subjected to standard techniques for correlation, regression, and analysis of variance.
Results
Recognised side effects associated with theophylline were commonly encountered. Eight subjects complained of gastrointestinal BRITISH MEDICAL JOURNAL VOLUME 289 15 DECEMBER 1984 disturbance with the 600 mg dose, and the 800 mg increment was not given to four of these. Of the 16 subjects given 800 mg, 14 developed similar side effects or others-namely, insomnia or headache. Two subjects felt too unwell to perform exercises after the 800 mg increment. All subjects completed the protocol as far as and including the 600 mg incremental dose, and those results were submitted for statistical analysis.
Theophylline dosage correlated closely with plasma theophylline concentrations measured 12 hours later (r2=0-9) and accounted for 40 for each incremental dose of oral theophylline as follows: 200 mg, 3-11 mg/l; 400 mg, 5 0-19 9 mg/l; 600 mg, 8-31 mg/l; 800 mg, 14-42 mg/l (n = 16).
There was no statistically significant correlation between six minute distances and theophylline dose (r2=0 1) or plasma theophylline concentrations (r2 = 0-08) (figs 1 and 2). These variables accounted for 0-10o and 000 (not significant (NS)) of the variation in these corridor walks. A significant increase in six minute distances (mean 21 m) was seen between baseline and placebo walks (p < 0 05; paired t test). The order of walks accounted for 3.50, (NS) of the variation in six minute distances; thus the later walks did not influence the results as might be expected from a training or experience effect.
There was no significant correlation between either the dose or the resultant plasma theophylline concentration and the breathlessness accompanying these exercises (r2=02 and r2= 0 18 respectively). Dose of theophylline accounted for 0-6% (NS) and plasma theophylline concentration 000' (NS) of the variation in these dyspnoea scores.
In this series theophylline produced no significant improvement in either FEV, or FVC. Overall PEFR similarly showed no improvement, although in a few patients a beneficial effect was seen. In the analysis of variance there was therefore a significant patient-theophylline interaction factor which accounted for 14"0 of the total variation in PEFR.
Heart rates increased with plasma theophylline concentrations (p < 0 01), mean increases of 0-74/min (before exercise) and 0 62/min (after exercise) being recorded per unit mg/l rise in plasma theophylline value. 
Discussion
The six minute corridor walk8 is an accurate, routine standard test of effort tolerance in patients with respiratory disease. Use of the test and the design of this study appeared to have been satisfactory in that variations in walking distances were not prejudiced by walking order, experience, or training effects. Patients were selected carefully so as to exclude only those who might be considered as suffering from chronic asthma. The population studied was therefore representative of patients whom we commonly encounter with chronic bronchitis due to cigarette smoking.
As with some single dose studies of theophylline in chronic bronchitis2 the incremental dosages used here produced no useful improvement in spirometric values. Neither effort tolerance nor concomitant dyspnoea appeared to be influenced by the drug, even when unacceptably high dosages were used. The results were similar for those subjects who showed small improvements in PEFR and for those with or without accompanying emphysema. Leitch Nineteen of the 20 subjects in this study with chronic bronchitis had previously been prescribed long term oral theophylline, and the use of the drug in this condition is common practice. The role of theophylline in chronic bronchitis appears to be less controversial than before, but the routine, indiscriminate use of the drug in these patients seems difficult to justify.
Introduction
Current clinical convention dictates that because acute myocardial infarction may affect plasma lipid concentrations lipid measurement for the detection of hyperlipidaemia should be deferred until two to three months after the acute event.,- 4 We have re-examined the effect of acute myocardial infarction on plasma lipid values to see if these can be meaningfully assessed during the hospital admission.
Patients and methods
We studied 58 patients who survived for three months after myocardial infarction. All had been admitted to the coronary care
